Arthritis research & therapy
-
Arthritis Res. Ther. · Mar 2017
Clinical TrialTreatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
The effect of IL-1 blocking therapy on mucocutaneous manifestations of Behçet's disease is incompletely understood. ⋯ Anakinra at an optimal dose of 200 mg daily had an acceptable safety profile and was partially effective in the treatment of resistant oral and genital ulcers in Behçet's disease.
-
Arthritis Res. Ther. · Mar 2017
Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
During pregnancy, patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) can experience active disease, which might be influenced by adjustment of treatment around conception. The aim of this study was to identify possible risk factors of disease flares during pregnancy and to evaluate the effect of treatment in pregnant patients experiencing a flare. ⋯ On the basis of a risk-benefit analysis, to stabilize disease activity and to prevent a flare during pregnancy in patients with RA and axSpA, tailored medication including TNF inhibitors should be considered beyond conception.